OmniAb Enters Collaboration, License Agreement with Eli Lilly
By Connor Hart
OmniAb has entered a collaboration and license agreement with Eli Lilly for a new ion channel program expected to help enable the discovery of next-generation therapeutics.
OmniAb, which provides cutting-edge discovery research technology, said Monday it will receive an upfront payment and be eligible to receive up to $370 million in research, development and commercial milestone payments, as well as tiered royalties on global net sales.
The therapeutic target and modality are undisclosed.
Shares of OmniAb jumped about 22%, to $4.12, in premarket trading. Eli Lilly's stock was roughly flat.
"We are pleased to enter into this important new relationship with Lilly," OmniAb Chief Executive Matt Foehr said. "Lilly is focused on delivering medicines to address major unmet medical needs and our differentiated expertise and established technologies that relate to ion channels are well positioned to help drive this new discovery program."
Write to Connor Hart at connor.hart@wsj.com
(END) Dow Jones Newswires
August 17, 2026 07:07 ET (11:07 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
4 Stocks to Buy Before They Rise Further
2 Undervalued Stocks to Buy Before They Rebound
The 10 Best Companies to Invest in Now
The 10 Best Dividend Stocks
United States